Soligenix Inc. (SNGX) Receives “Buy” Rating from Maxim Group

Soligenix Inc. (NASDAQ:SNGX)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a research report issued on Wednesday. They currently have a $5.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 122.22% from the company’s current price.

The analysts wrote, “Soligenix just announced yet another grant, this time $1.5M from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institute of Health (NIH) Small Business Innovation Research (SBIR) grant.””

Separately, HC Wainwright set a $11.00 price objective on Soligenix and gave the company a “buy” rating in a research report on Monday, August 14th.

Shares of Soligenix (SNGX) opened at 2.25 on Wednesday. Soligenix has a 12 month low of $1.90 and a 12 month high of $8.50. The stock’s market capitalization is $12.88 million. The company’s 50 day moving average price is $2.18 and its 200-day moving average price is $2.43.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Friday, August 11th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.09). The business had revenue of $1.00 million during the quarter, compared to the consensus estimate of $1.43 million. Soligenix had a negative net margin of 86.15% and a negative return on equity of 129.88%. Equities analysts predict that Soligenix will post ($1.48) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Soligenix Inc. (SNGX) Receives “Buy” Rating from Maxim Group” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at

Soligenix Company Profile

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply